JP2009531376A5 - - Google Patents

Download PDF

Info

Publication number
JP2009531376A5
JP2009531376A5 JP2009502034A JP2009502034A JP2009531376A5 JP 2009531376 A5 JP2009531376 A5 JP 2009531376A5 JP 2009502034 A JP2009502034 A JP 2009502034A JP 2009502034 A JP2009502034 A JP 2009502034A JP 2009531376 A5 JP2009531376 A5 JP 2009531376A5
Authority
JP
Japan
Prior art keywords
ylmethyl
cyclopropylpiperazin
benzothiazole
isopropylpiperazin
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2009502034A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009531376A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2007/052751 external-priority patent/WO2007110364A1/en
Publication of JP2009531376A publication Critical patent/JP2009531376A/ja
Publication of JP2009531376A5 publication Critical patent/JP2009531376A5/ja
Pending legal-status Critical Current

Links

JP2009502034A 2006-03-28 2007-03-22 ヒスタミンｈ３受容体活性を有するベンゾチアゾール Pending JP2009531376A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
EP06111820 2006-03-28
US78747806P 2006-03-30 2006-03-30
EP06112425 2006-04-10
US79428806P 2006-04-21 2006-04-21
EP06026875 2006-12-24
US90350307P 2007-02-26 2007-02-26
PCT/EP2007/052751 WO2007110364A1 (en) 2006-03-28 2007-03-22 Benzothiazoles having histamine h3 receptor activity

Publications (2)

Publication Number Publication Date
JP2009531376A JP2009531376A (ja) 2009-09-03
JP2009531376A5 true JP2009531376A5 (enExample) 2011-12-01

Family

ID=43124961

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009502034A Pending JP2009531376A (ja) 2006-03-28 2007-03-22 ヒスタミンｈ３受容体活性を有するベンゾチアゾール

Country Status (15)

Country Link
US (2) US8394842B2 (enExample)
EP (1) EP1999120B1 (enExample)
JP (1) JP2009531376A (enExample)
KR (1) KR101280333B1 (enExample)
CN (1) CN101410385B (enExample)
AU (1) AU2007229492B2 (enExample)
CA (1) CA2645581A1 (enExample)
EA (1) EA015569B1 (enExample)
ES (1) ES2388681T3 (enExample)
IL (1) IL193441A0 (enExample)
MX (1) MX2008011123A (enExample)
NZ (1) NZ570524A (enExample)
SG (1) SG170785A1 (enExample)
WO (1) WO2007110364A1 (enExample)
ZA (1) ZA200806985B (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030236259A1 (en) * 2002-02-05 2003-12-25 Rolf Hohlweg Novel aryl- and heteroarylpiperazines
ES2375929T3 (es) * 2005-07-04 2012-03-07 High Point Pharmaceuticals, Llc Antagonistas del receptor histamina h3.
CA2653062A1 (en) * 2006-05-23 2007-11-29 Transtech Pharma, Inc. 6- (4-cyclopropylpiperazin-1-yl) -2 ' -methyl- [3, 4 ' ] -bipyridine and its use as a medicament
HRP20120227T1 (hr) * 2006-05-29 2012-04-30 High Point Pharmaceuticals 3-(1,3-benzodioksol-5-il)-6-(4-ciklopropilpiperazin-1-il)piridazin, njegove soli i solvati te njegova uporaba kao antagonista histaminskog h3 receptora
EP2014656A3 (en) * 2007-06-11 2011-08-24 High Point Pharmaceuticals, LLC New heteocyclic h3 antagonists
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
US8153813B2 (en) * 2007-12-20 2012-04-10 Abbott Laboratories Benzothiazole and benzooxazole derivatives and methods of use
UY32275A (es) * 2009-03-24 2010-06-30 Sanofi Aventis DERIVADOS DE AZACARBOLINAS 9H-PIRROLO[2,3-b:5,4-c'] DIPIRIDINA, SU PREPARACION Y SU UTILIZACIÓN TERAPÉUTICA.
US8481547B2 (en) * 2009-12-18 2013-07-09 Janssen Pharmaceutica Nv Substituted benzothiazole and benzoxazole derivatives useful as inhibitors of DPP-1
HUE028435T2 (en) * 2010-09-02 2016-12-28 Suven Life Sciences Ltd Heterocyclic compounds as histamine H3 receptor ligands
WO2012120056A1 (de) 2011-03-08 2012-09-13 Sanofi Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2766349B1 (de) 2011-03-08 2016-06-01 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2683699B1 (de) 2011-03-08 2015-06-24 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2683704B1 (de) 2011-03-08 2014-12-17 Sanofi Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120054A1 (de) 2011-03-08 2012-09-13 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012170867A1 (en) 2011-06-09 2012-12-13 Rhizen Pharmaceuticals Sa Novel compounds as modulators of gpr-119
AU2012322095B2 (en) * 2011-10-14 2017-06-29 Ambit Biosciences Corporation Heterocyclic compounds and use thereof as modulators of type III receptor tyrosine kinases
EP3009424B1 (en) * 2013-06-10 2017-12-20 Astellas Pharma Inc. Bicyclic nitrogen-containing aromatic heterocyclic amide compound
JP6802194B2 (ja) 2015-06-22 2020-12-16 アクテリオン ファーマシューティカルズ リミテッドＡｃｔｅｌｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｌｔｄ Ｎａｄｐｈオキシダーゼ４阻害剤
AU2017231781C1 (en) * 2016-03-11 2021-12-16 Ac Immune Sa Bicyclic compounds for diagnosis and therapy
CN106588808A (zh) * 2017-02-26 2017-04-26 长沙深橙生物科技有限公司 一种苯并[d]恶唑衍生物的制备方法
US11407753B2 (en) 2017-06-05 2022-08-09 Ptc Therapeutics, Inc. Compounds for treating Huntington's disease
KR20210005559A (ko) 2018-03-27 2021-01-14 피티씨 테라퓨틱스, 인크. 헌팅턴병 치료 화합물
LT3814357T (lt) 2018-06-27 2024-06-25 Ptc Therapeutics, Inc. Heterocikliniai ir heteroarilų junginiai, skirti hantingtono ligos gydymui
WO2020005877A1 (en) * 2018-06-27 2020-01-02 Ptc Therapeutics, Inc. Heteroaryl compounds for treating huntington's disease
KR102682408B1 (ko) * 2021-05-12 2024-07-05 에이치케이이노엔 주식회사 신규한 벤조티아졸 유도체, 이의 제조방법 및 이의 간질환 예방 또는 치료 용도

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ187474A (en) * 1977-06-10 1981-03-16 Science Union & Cie 4-heterocyclyl-piperazine-i-carbodithioic acids and salts and pharmaceutical compositions thereof
NO156497C (no) 1984-10-18 1987-09-30 Helge Boe Anordning for sammenfoeyning av to plateformede elementer.
DE3511110A1 (de) 1985-03-27 1986-10-02 Dr. Karl Thomae Gmbh, 7950 Biberach Neue pyridazinone, ihre herstellung und diese verbindungen enthaltende arzneimittel
PH25772A (en) 1985-08-30 1991-10-18 Novo Industri As Insulin analogues, process for their preparation
FI91859C (fi) 1987-06-17 1994-08-25 Eisai Co Ltd Analogiamenetelmä antiallergisena aineena aktiivisen bentsotiatsolijohdannaisen valmistamiseksi
DE3837825A1 (de) 1988-11-08 1990-05-10 Hoechst Ag Neue insulinderivate, ihre verwendung und eine sie enthaltende pharmazeutische zubereitung
JP2869561B2 (ja) * 1989-05-22 1999-03-10 大塚製薬株式会社 血小板粘着抑制剤
JP2637303B2 (ja) * 1991-04-16 1997-08-06 明治製菓株式会社 新規ベンゾチアゾール誘導体
DE4223589A1 (de) 1992-07-17 1994-01-20 Fluehs Drehtechnik Gmbh Ventiloberteil
WO1994022846A1 (en) 1993-03-30 1994-10-13 Pfizer Inc. Compounds enhancing antitumor activity of other cytotoxic agents
JP3193560B2 (ja) 1993-04-16 2001-07-30 明治製菓株式会社 新規ベンゾオキサゾール誘導体
WO1995000550A1 (en) 1993-06-21 1995-01-05 Novo Nordisk A/S Aspb28 insulin crystals
BR9407508A (pt) 1993-09-17 1997-01-07 Novo Nordisk As Derivado de insulina composição farmaceutica e processo para o tratamento de diabete em um paciente com necessidade deste tratamento
US5504188A (en) 1994-06-16 1996-04-02 Eli Lilly And Company Preparation of stable zinc insulin analog crystals
US6130217A (en) 1995-09-20 2000-10-10 Pfizer Inc Compounds enhancing antitumor activity of other cytotoxic agents
WO1997026265A1 (en) 1996-01-17 1997-07-24 Novo Nordisk A/S Fused 1,2,4-thiadiazine and fused 1,4-thiazine derivatives, their preparation and use
JP3520177B2 (ja) 1996-05-09 2004-04-19 明治製菓株式会社 セロトニン５−ｈｔ３受容体部分活性薬
EP0923580A1 (en) 1996-07-26 1999-06-23 Dr. Reddy's Research Foundation Thiazolidinedione compounds having antidiabetic, hypolipidaemic, antihypertensive properties, process for their preparation and pharmaceutical compositions thereof
JP3149958B2 (ja) 1996-08-30 2001-03-26 ノボ ノルディスク アクティーゼルスカブ Ｇｌｐ―１誘導体
PT958296E (pt) 1996-12-31 2003-11-28 Reddys Lab Ltd Dr Compostos heterociclicos processo para a sua preparacao composicoes farmaceuticas contendo-os e sua utilizacao no tratamento da diabetes e doencas relacionadas
WO1997041119A1 (en) 1997-05-02 1997-11-06 Dr. Reddy's Research Foundation Novel antidiabetic compounds having hypolipidaemic, antihypertensive properties, process for their preparation and pharmaceutical compositions containing them
US6613942B1 (en) 1997-07-01 2003-09-02 Novo Nordisk A/S Glucagon antagonists/inverse agonists
JP2003514508A (ja) 1997-07-01 2003-04-15 ノボ ノルディスク アクティーゼルスカブ グルカゴン拮抗剤／逆作用剤
KR20010021936A (ko) 1997-07-16 2001-03-15 한센 핀 베네드, 안네 제헤르, 웨이콥 마리안느 융합된 1,2,4-티아디아진 유도체, 그의 제조와 사용
EP0927992A4 (en) 1997-07-17 1999-09-15 Sony Corp MAGNETIC RECORDING MEDIUM AND MAGNETIC RECORDING / REPRODUCING DEVICE COMPRISING SAME
WO1999019313A1 (en) 1997-10-27 1999-04-22 Dr. Reddy's Research Foundation Novel tricyclic compounds and their use in medicine; process for their preparation and pharmaceutical compositions containing them
US6440961B1 (en) 1997-10-27 2002-08-27 Dr. Reddy's Research Foundation Tricyclic compounds and their use in medicine: process for their preparation and pharmaceutical compositions containing them
SI20324A (sl) 1997-10-27 2001-02-28 Agouron Pharmaceuticals, Inc. Substituirane 4-amino-tiazol-2-il spojine kot cdk inhibitorji
DE69803750T2 (de) 1997-12-02 2002-09-12 Dr. Reddy's Research Foundation, Andhra Pradesh Thiazolidinedione- und oxazolidinedione-derivate mit antidiabetischen, hypolipidämischen und anti hypertensiven eigenschaften
JPH11199573A (ja) * 1998-01-07 1999-07-27 Yamanouchi Pharmaceut Co Ltd ５ｈｔ３受容体作動薬及び新規ベンゾチアゾール誘導体
EP1123268A1 (en) 1998-10-21 2001-08-16 Novo Nordisk A/S New compounds, their preparation and use
EP1123269A1 (en) 1998-10-21 2001-08-16 Novo Nordisk A/S New compounds, their preparation and use
EP1123267A1 (en) 1998-10-21 2001-08-16 Novo Nordisk A/S New compounds, their preparation and use
WO2000023425A1 (en) 1998-10-21 2000-04-27 Novo Nordisk A/S New compounds, their preparation and use
EP1123292A1 (en) 1998-10-21 2001-08-16 Novo Nordisk A/S New compounds, their preparation and use
JP2002527520A (ja) 1998-10-21 2002-08-27 ノボ ノルディスク アクティーゼルスカブ 新規化合物、その製造及び使用
WO2000029409A1 (de) 1998-11-17 2000-05-25 Bayer Aktiengesellschaft Neue heterocyclyl-substituierte oxazolidon-derivate
TW520370B (en) * 1998-11-20 2003-02-11 Meiji Seika Kaisha Benzooxazole derivatives and a pharmaceutical composition containing the derivatives as an active ingredient
DE69908648T2 (de) 1998-12-18 2004-05-13 Novo Nordisk A/S Kondensierte 1,2,4-thiadiazinderivate, ihre herstellung und verwendung
WO2000041121A1 (en) 1999-01-07 2000-07-13 Ccrewards.Com Method and arrangement for issuance and management of digital coupons and sales offers
EP1147094A1 (en) 1999-01-15 2001-10-24 Novo Nordisk A/S Non-peptide glp-1 agonists
AU4465200A (en) 1999-04-16 2000-11-02 Dr. Reddy's Research Foundation Novel polymorphic forms of an antidiabetic agent: process for their preparation and a pharmaceutical composition containing them
WO2000063191A1 (en) 1999-04-16 2000-10-26 Dr. Reddy's Research Foundation Novel polymorphic forms of an antidiabetic agent: process for their preparation and a pharmaceutical composition containing them
PL351492A1 (en) 1999-04-16 2003-04-22 Reddys Lab Ltd Dr Novel polymorphic forms of an antidiabetic agent: process for their preparation and pharmaceutical compositions containing them
AU3958100A (en) 1999-04-20 2000-11-02 Novo Nordisk A/S New compounds, their preparation and use
JP2002542237A (ja) 1999-04-20 2002-12-10 ノボ ノルディスク アクティーゼルスカブ 新規な化合物、それらの製造及び使用
BR0009864A (pt) 1999-04-20 2002-01-08 Novo Nordisk As Composto, composição farmacêutica, métodos para o tratamento de doenças, para o tratamento e/ou prevenção de condições mediadas pelos receptores nucleares e para o tratamento e/ou prevenção de diabete e/ou obesidade, e, uso de um composto
WO2000063196A1 (en) 1999-04-20 2000-10-26 Novo Nordisk A/S New compounds, their preparation and use
GB0003254D0 (en) 2000-02-11 2000-04-05 Darwin Discovery Ltd Heterocyclic compounds and their therapeutic use
AU2001247906A1 (en) 2000-03-31 2001-10-15 Ortho-Mcneil Pharmaceutical, Inc. Phenyl-substituted indoles and indazoles
WO2001074810A2 (en) 2000-03-31 2001-10-11 Ortho Mcneil Pharmaceutical, Inc. Method for using 2-aryloxyalkylaminobenzoxazoles and 2-aryloxyalkylaminobenzothiazoles as h3 antagonists
DK1308439T3 (da) * 2000-08-10 2009-01-12 Mitsubishi Tanabe Pharma Corp Prolinderivater og anvendelse af disse som lægemidler
US20030073672A1 (en) * 2001-09-05 2003-04-17 Breitenbucher J. Guy Method for treating allergies using substituted pyrazoles
US7576084B2 (en) 2001-10-12 2009-08-18 Choongwae Pharma Corporation Reverse-turn mimetics and method relating thereto
AU2003203148A1 (en) * 2002-02-05 2003-09-02 High Point Pharmaceuticals, Llc Novel aryl- and heteroarylpiperazines
US7449464B2 (en) * 2003-03-12 2008-11-11 Kudos Pharmaceuticals Limited Phthalazinone derivatives
EP1620434B1 (en) * 2003-05-07 2011-03-09 Abbott Laboratories Fused bicyclic-substituted amines as histamine-3 receptor ligands
TW200538433A (en) 2004-02-24 2005-12-01 Irm Llc Immunosuppressant compounds and compositiions
CA2622677A1 (en) 2005-09-23 2007-04-05 Richard Schumacher Indazoles, benzothiazoles, benzoisothiazoles, benzisoxazoles, pyrazolopyridines, isothiazolopyridines, and preparation and uses thereof

Similar Documents

Publication Publication Date Title
JP2009531376A5 (enExample)
JP2009523760A5 (enExample)
JP2012533546A5 (enExample)
JP2006526590A5 (enExample)
JP2009502743A5 (enExample)
JP2016518437A5 (enExample)
JP2012532874A5 (enExample)
JP2010511721A5 (enExample)
JP2011529054A5 (enExample)
JP2017537940A5 (enExample)
JP2011513410A5 (enExample)
JP2011505347A5 (enExample)
JP2013514980A5 (enExample)
JP2014500861A5 (enExample)
JP2013542261A5 (enExample)
JP2003503449A5 (enExample)
JP2011529502A5 (enExample)
JP2010520214A5 (enExample)
JP2006528617A5 (enExample)
JP2012509263A5 (enExample)
JP2012507535A5 (enExample)
JP2012519182A5 (enExample)
JP2015535847A5 (enExample)
JP2010523591A5 (enExample)
JP2006501201A5 (enExample)